DUBLIN – Polyprox Therapeutics Ltd. is the latest contender to enter the promising but increasingly crowded space of harnessing the proteasome for therapeutic effect. The company, a newly launched spinout from the University of Cambridge, is based on more than a decade of research conducted by its founder and chief scientific officer, Laura Itzhaki, who is professor of structural pharmacology at Cambridge and an expert on protein structure, protein folding, protein-protein interactions and protein engineering.